• Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214 americanpharmaceuticalreview
    September 14, 2020
    Viking Therapeutics announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK0214, a novel, orally available thyroid receptor beta (TRβ) agonist in development as a potential treatment for ...
PharmaSources Customer Service